How should withdrawal from cocaine and Δ9‑tetrahydrocannabinol (THC) be managed in an adult outpatient psychiatric patient with stable co‑occurring psychiatric disorder and no severe medical comorbidities?

Managing Cocaine and THC Withdrawal in Outpatient Psychiatry

For cocaine withdrawal in an outpatient psychiatric setting, implement contingency management combined with community reinforcement approach as first-line treatment, while THC withdrawal should be managed with supportive counseling and psychoeducation, as no medications are currently approved for either condition.

Cocaine Withdrawal Management

Primary Treatment Approach

The evidence strongly supports contingency management (CM) plus community reinforcement approach (CRA) as the most effective intervention for cocaine addiction 1. This combination demonstrates:

• Superior efficacy: 4 patients need treatment to achieve 1 additional abstinent patient versus treatment as usual (NNT 4.07)
• Better retention: 3 patients need treatment to prevent 1 dropout (NNT 3.25)
• Long-term benefits: Maintains superiority at longest follow-up (NNT 3.68)

Contingency management involves providing tangible rewards (vouchers, incentives) for drug-free urine samples. Community reinforcement approach is multi-layered, incorporating:

• Functional analysis of substance use triggers
• Coping-skills training
• Social, familial, recreational, and vocational reinforcements

Alternative Psychosocial Interventions

If CM plus CRA is unavailable, consider these ranked alternatives 1:

1. CM plus CBT: NNT 4.80 for abstinence versus treatment as usual
2. CM alone: NNT 5.44 for abstinence versus treatment as usual
3. CRA alone: Shows efficacy but less robust than combinations

Important caveat: CBT alone and 12-step programs, despite being recommended in older guidelines, show limited efficacy—CBT is more acceptable than treatment as usual (NNT 10.5) but does not significantly improve abstinence rates 1.

Pharmacological Considerations

No medications are FDA-approved for cocaine withdrawal 2. Limited evidence suggests potential benefit from:

• Mirtazapine, naltrexone, or bupropion during acute (first week) and protracted withdrawal phases 2
• These remain off-label and should only be considered for managing specific withdrawal symptoms (anxiety, sleep disturbance, depression)

For patients with comorbid psychiatric disorders, risperidone has shown promise in reducing craving and improving treatment completion (88% vs 32% historical completion rate), though this is based on a small naturalistic trial 3.

THC (Cannabis) Withdrawal Management

Clinical Recognition

Cannabis withdrawal occurs in approximately 50% of regular users after cessation 4. Key features to monitor:

• Onset: 24-48 hours after cessation
• Peak symptoms: Days 2-6
• Duration: Most symptoms resolve within 3 weeks; some persist longer in heavy users

Common symptoms (in order of frequency):

• Anxiety, irritability, anger/aggression
• Disturbed sleep/vivid dreams
• Depressed mood
• Loss of appetite

Less common physical symptoms: Chills, headaches, physical tension, sweating, stomach pain

Primary Treatment Approach

Supportive counseling and psychoeducation are first-line management 4. Despite limited empirical evidence, this remains the standard approach because:

1. No medications are FDA-approved specifically for cannabis withdrawal
2. Pharmacological trials have been underpowered with unreplicated findings 4

Symptomatic Management

When withdrawal symptoms are severe, consider short-term symptomatic treatment:

• Anxiety: Short-acting benzodiazepines (use cautiously, limited duration)
• Sleep disturbance: Non-benzodiazepine hypnotics or trazodone
• Nausea: Antiemetics as needed

Off-label cannabis agonists (synthetic cannabinoids) are used in some clinical settings but lack robust evidence 4.

When to Consider Inpatient Care

Admit for medically-assisted withdrawal if:

• Significant comorbid mental health disorders (psychosis, severe depression, suicidal ideation)
• Polysubstance use requiring concurrent management
• Previous failed outpatient attempts with severe complications 4

Integrated Management for Dual Withdrawal

Assessment Priorities

When managing both cocaine and THC withdrawal simultaneously:

1. Screen for polysubstance use: Alcohol, opioids, benzodiazepines require different withdrawal protocols 5
2. Assess psychiatric comorbidities: Depression, PTSD, and anxiety disorders affect retention and outcomes 6
3. Evaluate withdrawal severity: Cocaine withdrawal is primarily psychological; THC withdrawal has both psychological and physical components

Treatment Sequencing

Address cocaine dependence as the priority given:

• Higher morbidity and mortality risk
• Stronger evidence base for effective interventions
• Cannabis use disorder may predict shorter retention in cocaine treatment 6

However, do not ignore cannabis withdrawal symptoms, as they may precipitate relapse to both substances 4.

Monitoring Strategy

Weekly assessments should include:

• Urine drug testing (expect gradual improvement, not immediate abstinence)
• Craving intensity (use standardized scales)
• Withdrawal symptom severity
• Treatment adherence and engagement
• Psychiatric symptom stability

Critical Pitfalls to Avoid

1. Do not rely solely on CBT or 12-step programs for cocaine—evidence shows these are insufficient as monotherapy 1

2. Do not prescribe medications as primary treatment for either withdrawal syndrome without addressing psychosocial interventions first 4, 2

3. Do not abruptly discontinue cannabis in patients on medical cannabis without substitution planning, as this risks withdrawal syndrome 7

4. Do not underestimate withdrawal severity: Both can precipitate relapse and worsen psychiatric comorbidities 4, 8

5. Do not mandate immediate abstinence: Harm reduction strategies (reducing use, safer use practices) are appropriate when patients are not committed to complete abstinence 5

Practical Implementation

Establish clear contingencies for CM:

• Define specific behavioral targets (negative urine tests, session attendance)
• Provide immediate, tangible rewards
• Escalate reward value with consecutive achievements
• Reset (but don't eliminate) after relapse

Structure CRA components:

• Identify high-risk situations and triggers
• Develop alternative rewarding activities
• Involve family/social supports when appropriate
• Address vocational and recreational deficits

Maintain longitudinal approach: Substance dependence is chronic and relapsing; expect setbacks and maintain therapeutic alliance through relapses 5.